Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of GAIA-102 alone or with pembrolizumab in advanced or relapsed non-small cell lung cancer
jRCT2073210080Phase 2Completed
- Sponsor
- GAIA BioMedicine
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of GAIA-102 and pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by GAIA BioMedicine. Primary endpoints: Dose-limiting toxicity, Adverse events and 1 more. Started Dec 2021; status: completed.
02
Drugs
GAIA-102pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2073210080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073210080.